Overview
CLOUDBREAK-B (2592)
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company dev...
- Open
- 1.190
- High
- 1.190
- Low
- 1.190
- Prev. Close
- 1.190
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- 0.00%
- 52wk High
- 9.580
- Volume Ratio
- 0.00
- Turnover Ratio
- --
- 52wk Low
- 0.900
- HK Mkt Cap
- 1.10B
- Market CapHKD
- 1.10B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -1.02
- EPSDynamic
- -0.813
- EPSStatic
- --
- BVPS
- 0.36
- P/B
- 3.34
- HK Shares
- 924.69M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 924.69M
- Min lot size
- 500
- Currency
- HKD
Daily Events
- Aug, 26
Cloudbreak Pharma opened lower and rallied in the morning session, reaching HKD 1.225 as of 9:50 BJ, up 5.6% from the prior close of HKD 1.160, with intraday low at HKD 1.195 and high at HKD 1.225 on thin volume of 19,500 shares. The move was driven by the company's announcement of a board meeting to review interim results and consider dividend declaration, coupled with recent news of a share subscription agreement with ARC Group International for up to US$15 million and FDA safety clearance for its CBT-358 clinical program. However, its fundamentals remain challenged: Q4 2025 revenue plunged 97.79% YoY to HKD 875,224, while net loss widened to HKD 283 million, with EPS of -HKD 0.3381. The stock is down 87.21% from its 52-week high of HKD 9.58 and 72.84% year-to-date, currently trading above its 20-day MA (HKD 1.183) but slightly below the 60-day MA (HKD 1.229), with a PB of 2.41x and negative PE.
- Aug, 18
Cloudbreak Pharma (2592.HK) experienced a single-sided decline during the morning session, opening lower at HKD 1.160 and continuously weakening, with the intraday low hitting HKD 1.080 before closing at HKD 1.085, down 7.26%, with turnover of only HKD 116,500 indicating thin trading. The company recently completed a series of share placements, with a next-day disclosure return on August 6 showing a 41.7 million share increase in share capital, following a 22,848,000 share increase in July, and the continued dilution is pressuring the stock. Meanwhile, despite R&D pipeline progress, Q4 2025 financials showed revenue of just HKD 875,224, down 97.79% YoY, and a net loss of HKD 283.4 million, widening 55.22% YoY, with a net profit margin of -32,376%, indicating deep fundamental weakness. The stock is now 88.67% below its 52-week high of HKD 9.58, and trades below both the 20-day MA of HKD 1.212 and the 60-day MA of HKD 1.238, though it has already declined 75.94% YTD, and the company did secure a share subscription agreement with ARC Group for up to US$15 million, providing some liquidity buffer.
- Aug, 12
Cloudbreak Pharma opened lower and extended losses to close the morning session 6.05% lower at HKD 1.16, driven by frequent capital activities including a share subscription agreement with ARC Group International for up to US$15 million and multiple prior equity disclosures, raising dilution concerns. The appointment of a new company secretary and authorized representative also drew market attention. Financially, Q4 2025 operating revenue plunged 97.79% YoY to just HKD 875,224, with an EPS loss of HKD 0.3381 showing no significant narrowing, underscoring challenging fundamentals. The stock has retreated 87.84% from its 52-week high of HKD 9.58 and is down 74.17% YTD, trading well below both the 20-day MA (HKD 1.249) and 60-day MA (HKD 1.252). However, the company's pipeline progress — including CBT-001 in Phase III MRCT, completed Phase I/II for CBT-009, and recent FDA clearance for CBT-358 — may offer medium-term support.
- Jul, 31
拨康视云制药午后开盘即跳空高开,并以 1.220 港元收盘,较前收 1.150 港元上涨 6.09%,日内波动区间为 1.130 至 1.220 港元,形成典型的低开高走形态。早盘成交清淡仅 6.6 万股,但下午开盘后成交量激增至约 140.95 万股,推动股价快速拉升,主因是公司获得美国 FDA 安全许可,启动 CBT-358 的临床研究,同时与 ARC Group International 签署最高 1500 万美元的股份认购协议。不过,当前股价仅略高于 20 日均线(1.286 港元)和 60 日均线(1.29 港元),且距 52 周高点 9.58 港元仍下跌 87.27%,今年迄今跌幅达 72.95%,显示估值修复压力较大。近期公司还从 Cedar Wealth 仲裁案中脱身,但仍面临持续亏损——最近季度净利润亏损约 2.83 亿港元,营收同比骤降 97.79%。
- Jul, 20
Cloudbreak Pharma staged a rebound today, closing at HKD 1.33, up 0.76% from the open of HKD 1.32, despite an intraday low of HKD 1.25. The stock, down 86.12% from its 52-week high of HKD 9.58 and 70.51% YTD, rallied in the afternoon session on FDA clearance to begin a Phase 3 clinical trial for CBT-001 and a share subscription agreement with ARC Group International for up to USD 15 million, reaching an intraday high of HKD 1.35. The recovery brought the price close to the 60-day moving average of HKD 1.34. However, the company reported a net loss of HKD 283.36 million in Q4 2025, widening 55.22% YoY, with revenue plummeting 97.79% YoY, underscoring persistent fundamental weakness.
News
PUBT · Cloudbreak Pharma Relocates Hong Kong Principal Place of Business to Harbour City
Tip Ranks · Cloudbreak Reports Positive Phase 3 Results for CBT-001
Global Report · Legend's Reported Bank Exit Anchors a Week of Balance-Sheet Moves in Hong Kong
Weekly Review · Weekly Recap | CLOUDBREAK-B this week, suspended amid IPO manipulation probe
